Currently licensed COVID-19 vaccines are all designed for intramuscular (IM) immunization.
However, vaccination today failed to prevent the virus infection through the upper respiratory …

Viruses lacking the capacity to infect mammals exhibit minimal toxicity, good
biocompatibility, and well-defined structures. As self-organized biomolecular assemblies …

The ongoing COVID-19 pandemic drew global attention to infectious diseases, attracting
numerous resources for development of pandemic preparedness plans and vaccine …

The COVID-19 pandemic has highlighted the need for efficient vaccine platforms that can
rapidly be developed and manufactured on a large scale to immunize the population against …

The lack of knowledge about the absorption, distribution, metabolism, and excretion (ADME)
of vaccines makes biopharmaceutical optimization difficult. This was shown during the …

Highlights•NDV platform allows rapid development of live vaccines against emerging
pathogens.•NDV vectors are stable, safe, easy to propagate, and administer.•Improved …

Background In order to prevent the emergence and spread of future variants of concern of
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), developing vaccines …

The rapid development and deployment of vaccines following the emergence of severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been estimated to have saved …

Despite global vaccination efforts, severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) continues to evolve and spread globally. Currently, the development of affordable …

The emergence of SARS-CoV-2 in December 2019 resulted in the COVID-19 pandemic.
Recurring disease outbreaks repeatedly overloaded the public health sector and severely …